IN2014DN05866A - - Google Patents

Info

Publication number
IN2014DN05866A
IN2014DN05866A IN5866DEN2014A IN2014DN05866A IN 2014DN05866 A IN2014DN05866 A IN 2014DN05866A IN 5866DEN2014 A IN5866DEN2014 A IN 5866DEN2014A IN 2014DN05866 A IN2014DN05866 A IN 2014DN05866A
Authority
IN
India
Prior art keywords
methods
chlorate
medicaments
mixture
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Rainer Martin
Jürgen Arnhold
Robert Seifert
SMITH Dominic KING
Tejas Desai
Andreas Wagner
Original Assignee
Nuvo Res Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvo Res Gmbh filed Critical Nuvo Res Gmbh
Publication of IN2014DN05866A publication Critical patent/IN2014DN05866A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IN5866DEN2014 2011-12-22 2012-12-21 IN2014DN05866A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579326P 2011-12-22 2011-12-22
PCT/IB2012/057645 WO2013093891A1 (fr) 2011-12-22 2012-12-21 Compositions liposomales comprenant des chlorites ou chlorates

Publications (1)

Publication Number Publication Date
IN2014DN05866A true IN2014DN05866A (fr) 2015-05-22

Family

ID=47630448

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5866DEN2014 IN2014DN05866A (fr) 2011-12-22 2012-12-21

Country Status (11)

Country Link
US (1) US20130177629A1 (fr)
EP (1) EP2793860A1 (fr)
JP (1) JP2015502400A (fr)
CN (1) CN104125826A (fr)
AU (1) AU2012297589C1 (fr)
BR (1) BR112014015333A2 (fr)
CA (1) CA2857604A1 (fr)
IN (1) IN2014DN05866A (fr)
MX (1) MX2014007664A (fr)
RU (1) RU2014130080A (fr)
WO (1) WO2013093891A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8226975B2 (en) 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2014037927A1 (fr) * 2012-09-10 2014-03-13 Nuvo Research Gmbh Compositions de chlorate et utilisation de chlorate dans le traitement de l'exposition aux rayonnements
EP2925298B1 (fr) 2012-11-29 2019-05-29 Insmed Incorporated Formulations de vancomycine stabilisées
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
NZ726256A (en) 2014-05-15 2022-11-25 Insmed Inc Methods for treating pulmonary non-tuberculous mycobacterial infections
BR112018003227A2 (pt) * 2015-08-20 2018-09-25 Oxo Chemie Thailand Co Ltd uso de clorito para tratar doenças dos glóbulos vermelhos e indicações mediadas desta forma
TWI719105B (zh) * 2016-01-04 2021-02-21 中央硏究院 基於酯化/皂化用於微脂體負載之方法
WO2019075202A2 (fr) * 2017-10-11 2019-04-18 California Institute Of Technology Procédés et système pour interférer avec la viabilité de bactéries, antimicrobiens associés et compositions
EP3752833A4 (fr) * 2018-02-15 2021-11-24 Yeditepe Universitesi Procédé d'isolement d'exosomes par un système de fluide à deux phases
EP3773505A4 (fr) 2018-03-30 2021-12-22 Insmed Incorporated Procédés pour la fabrication continue de produits médicamenteux liposomaux
CN110563829B (zh) * 2019-09-17 2021-03-26 中国人民解放军国防科技大学 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用
CN112716973A (zh) * 2019-10-28 2021-04-30 卢序 一种降低细胞还原应激的氧化剂的用途
TR202012260A2 (tr) * 2020-08-05 2020-10-21 Emin Zuemruetdal Oral kullanim i̇çi̇n potasyum hi̇droksi̇t/sodyum hi̇droksi̇t solüsyonu
US20230390331A1 (en) * 2022-05-19 2023-12-07 Neuvivo, Inc. Biomarkers For Neurogenerative Disease

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE3213389A1 (de) 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
US4551288A (en) 1982-08-16 1985-11-05 Sandoz, Inc. Processes for the preparation of liposome drug delivery systems
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4574084A (en) 1983-02-25 1986-03-04 Peter Berger Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
DE3515745A1 (de) 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
DE3625867C2 (de) 1986-07-31 1995-10-19 Elstner Erich F Prof Dr Verwendung von Tetrachlordecaoxid in der Ophthalmologie
US4752425A (en) 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US4781871A (en) 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
WO1988007850A1 (fr) 1987-04-16 1988-10-20 The Liposome Company, Inc. Procede et appareil pour reduire les dimensions des liposomes en continu
US5049390A (en) 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US4851222A (en) 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
CA2025907A1 (fr) 1989-09-21 1991-03-22 Franklin D. Collins Methode pour le transport de composes a travers la barriere hemato-encephalique
US5190822A (en) 1990-04-20 1993-03-02 Fuji Photo Film Co., Ltd. Surface-modifiable liposome and process for producing surface-modified liposome
US5206027A (en) 1990-09-13 1993-04-27 Fuji Photo Film Co., Ltd. Amphipathic compound and liposome comprising the same
WO1992007959A1 (fr) 1990-11-05 1992-05-14 Biowhittaker Inc. Procede de dosage immunologique lytique homogene sur membrane utilisant des formulations de liposomes sensibles au contact
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
JPH06206825A (ja) 1992-12-11 1994-07-26 Nippon Rooshiyon Kk 白癬菌、湿疹等による皮膚病の治療剤及び 皮膚殺菌活性化剤
EP0616801B1 (fr) 1993-03-24 1998-05-27 Novartis AG Procédé pour la préparation à haute pression d'une dispersion de liposomes
AU1552995A (en) 1993-12-17 1995-07-03 Spinal Cord Society Method for inducing dna synthesis in neurons
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6110666A (en) 1994-06-09 2000-08-29 Medical Research Council Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure
US5786214A (en) 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
JP3735921B2 (ja) 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
WO1999017787A2 (fr) 1997-10-06 1999-04-15 Oxo Chemie Ag Utilisation de solution de chlorite stabilisee par voie chimique aux fins de l'inhibition d'une reponse immunitaire specifique d'un antigene
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
ES2339421T3 (es) 1997-11-19 2010-05-20 Georgetown University Administracion genica mediante liposoma dirigido.
US6573101B1 (en) 1998-02-12 2003-06-03 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
US6077502A (en) 1998-02-27 2000-06-20 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6132702A (en) 1998-02-27 2000-10-17 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6251372B1 (en) 1998-02-27 2001-06-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6350438B1 (en) 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6245427B1 (en) 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
ATE289804T1 (de) 1998-10-08 2005-03-15 Hampar L Karagoezian Synergistische antimikrobielle. dermatologische und ophtahalmologische zubereitungen, die ein chlorit und wasserstoffperoxid enthalten
JP4727816B2 (ja) * 1998-10-08 2011-07-20 エル． カラジョージアン、ハンパー 亜塩素酸塩と過酸化水素とを含有する共同作用抗菌性皮膚科・眼科製剤
JP2001002592A (ja) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
EP1408994A2 (fr) 1999-08-18 2004-04-21 OXO Chemie AG Solutions de chlorite chimiquement stables, destinees au traitement du cancer et d'autres maladies
WO2001017030A1 (fr) 1999-08-27 2001-03-08 Macronix America, Inc. Structure de memoire non volatile permettant de stocker deux bits d'information et procede de fabrication
US20070104798A1 (en) * 1999-10-04 2007-05-10 S.K. Pharmaceuticals, Inc. Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide
ES2320193T3 (es) 1999-11-24 2009-05-20 Transave, Inc. Sistema de suministro liposomico dirigido modular.
OA12210A (en) 1999-12-30 2006-05-09 Judith K Gwathmey Iron chelator delivery system.
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
WO2003044214A2 (fr) 2001-11-20 2003-05-30 Baylor College Of Medicine Procedes et compositions mis en application dans la signalisation d'un point de controle
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
KR20030072766A (ko) * 2002-03-06 2003-09-19 (주)인터커머스 구취 억제능이 우수한 구강 위생용 조성물 및 그의제조방법
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8765808B2 (en) * 2005-03-23 2014-07-01 Chs Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
EP2428213A1 (fr) 2005-07-21 2012-03-14 Nuvo Research AG Solutions de chlorite stabilisées asociées à des fluoropyrimidines pour l'utilisation dans le traitement des cancers
CA2634915A1 (fr) 2005-12-22 2007-07-05 Taiji Biomedical, Inc. Formulations de chlorite et leurs procedes de preparation et d'utilisation
EP1971426A1 (fr) 2006-01-11 2008-09-24 P & W Invest Vermögensverwaltungsgesellschaft mbH Membrane d'enveloppe destinée à libérer un agent encapsulé, procédé de fabrication et utilisation
EP2164502A1 (fr) 2007-06-01 2010-03-24 Dimethaid AG Utilisation de wf10 pour traiter l'asthme allergique, la rhinite allergique et la dermite atopique
US20110052655A1 (en) 2007-08-08 2011-03-03 Wilson Kurt Whitekettle Methods and vesicles for controlling protozoa
EP2449114B9 (fr) * 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Formulations lipidiques inédites permettant l'administration d'agents thérapeutiques en direction de tumeurs solides
US20110177147A1 (en) 2010-01-21 2011-07-21 General Electric Company Stable biocidal delivery systems

Also Published As

Publication number Publication date
BR112014015333A8 (pt) 2017-06-13
AU2012297589C1 (en) 2015-04-16
MX2014007664A (es) 2015-05-11
AU2012297589A1 (en) 2013-07-11
BR112014015333A2 (pt) 2017-06-13
WO2013093891A1 (fr) 2013-06-27
AU2012297589B2 (en) 2014-10-30
US20130177629A1 (en) 2013-07-11
RU2014130080A (ru) 2016-02-10
CN104125826A (zh) 2014-10-29
EP2793860A1 (fr) 2014-10-29
JP2015502400A (ja) 2015-01-22
CA2857604A1 (fr) 2013-06-27

Similar Documents

Publication Publication Date Title
IN2014DN05866A (fr)
PH12015501439A1 (en) Oral care products comprising zinc oxide and trimethylglycine
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
IL221989A (en) Fat bubble preparations and methods of use
MX360391B (es) Composiciones liposomales combinadas para terapia contra el cancer.
EP2706988A4 (fr) Liposomes comprenant des lipides conjugués à un polymère et utilisations s'y rapportant
MX2015012200A (es) Composiciones de oxaliplatino en liposomas para la terapia contra el cancer.
MX351453B (es) Composiciones de liberacion sostenida a base de lipidos anfipaticos.
HK1199739A1 (en) Algal lipid compositions and methods of preparing and utilizing the same
PH12015501239A1 (en) Oral care products comprising tetrabasic zinc chloride and trimethylglycine
IL231951B (en) pam3cys-like stimulants and their use for the preparation of preparations
IL230463A0 (en) Benzamides, their preparation and pharmaceutical preparations containing them
MX2015012199A (es) Composiciones de cisplatino liposomal para la terapia contra el cancer.
EP3191102A4 (fr) Compositions de vésicules lipidiques multilamellaires et procédés d'utilisation
HK1198430A1 (en) Formulations and dosage forms of oxidized phospholipids
EP2663288A4 (fr) Procédé pour la préparation de vésicules et formulations produites à partir de celles-ci
MA40627A (fr) Formulations stables de lipides et de liposomes
EP3042652A4 (fr) Utilisation de composition contenant un chélate d'acide aminé ferreux pour la préparation de médicament anti-cancéreux
PL2757910T3 (pl) Produkt z mieszanego włókna do stosowania przy wytwarzaniu elementów filtracyjnych papierosa i odnośne sposoby
SG10201405125YA (en) Composition for hair cosmetic preparation and production method of the same
PT2665856T (pt) Formulações de agentes branqueadores fluorescentes na forma dispersa
PT2590509T (pt) Método para a preparação e utilização de biocidas enriquecidos em radicais ativos antes da utilização
PL2768561T3 (pl) Sposób produkcji aerozolowych zbiorników medycznych oraz dozownika zawierającego wspomniany zbiornik
IN2015DN04074A (fr)
WO2013072243A3 (fr) Subsitut de vaseline